

## 09. Cell Therapy in Solid Tumors

**P09.01 ADAPTING IMMUNE CELLS TO THE HYPOGLYCEMIC TUMOR MICROENVIRONMENT BY SOLUTE CARRIER 2A1 (SLC2A1/GLUT1) OVEREXPRESSION**

<sup>1,2,3</sup>ME Kirmaier\*, <sup>4</sup>BL Cadilha, <sup>1,2,3</sup>A Hadzic, <sup>5</sup>W Schmitz, <sup>4</sup>MR Benmebarek, <sup>4</sup>D Briukhovetska, <sup>4</sup>S Michaelides, <sup>6</sup>V Buschinger, <sup>1,7</sup>B Tast, <sup>4</sup>CH Bönigk, <sup>1,2,3</sup>S Ogenesian, <sup>1,2,3</sup>L Vona, <sup>1</sup>A Tischmacher, <sup>8</sup>V Heissmeyer, <sup>9</sup>M Vaeth, <sup>6</sup>VR Buchholz, <sup>5</sup>M Eilers, <sup>1,3</sup>M von Bergwelt-Baildon, <sup>1,7</sup>M Subklewe, <sup>4</sup>S Kobold, <sup>1,2,3</sup>S Theurich. <sup>1</sup>Department of Medicine III, LMU Klinikum, Munich, Germany; <sup>2</sup>Cancer and Immunometabolism Research Group, Gene Center, LMU Munich, Munich, Germany; <sup>3</sup>German Cancer Consortium (DKTK), Partner site Munich, Heidelberg, Germany; <sup>4</sup>Department of Medicine IV, Division of Clinical Pharmacology, LMU Munich, Munich, Germany; <sup>5</sup>Department of Biochemistry and Molecular Biology, Biocenter, JMU Würzburg, Würzburg, Germany; <sup>6</sup>Institute for Medical Microbiology, Immunology and Hygiene, TU Munich, Munich, Germany; <sup>7</sup>Translational Cancer Immunology Research Group, Gene Center, LMU Munich, Munich, Germany; <sup>8</sup>Institute for Immunology, LMU Munich, Biomedical Center Munich, Munich, Germany; <sup>9</sup>Institute of Systems Immunology, Max Planck Research Group, JMU Würzburg, Würzburg, Germany, Würzburg, Germany

10.1136/jitc-2024-ITOC10.45

**Background** In recent years, T cell-based immunotherapies have shown promising results in hematologic malignancies. However, these strategies seem to be limited in solid cancers, posing more complex challenges including a hostile TME with nutrient deprivation and tissue hypoxia [1]. Additionally, metabolic reprogramming has been identified as a crucial factor for proper cytotoxic T-cell functions upon their activation. Such energy demands are answered by the upregulation of glycolysis, oxidative phosphorylation, and upregulation of nutrient transporters represented by SLCs [2,3]. Within the TME, tumor and immune cells compete for nutrients and shape a distinct metabolic milieu, resulting in an ineffective effector function [4]. Herein, we aim to metabolically engineer T cells to improve their fitness in the glucose-deprived TME and optimize ACT.

**Materials and Methods** We retrovirally overexpressed the glucose transporter Slc2a1/GLUT1 in murine CD8<sup>+</sup> T cells (CD8<sup>+</sup>Slc2a1). To assess T-cell fitness we conducted experiments in physiologic (5mM) and hypoglycemic (0.5mM) media conditions. CellTrace<sup>TM</sup>-based proliferation experiments and killing assays in the OT1-OVA model are used to examine differences to MOCK in functionality and were analyzed via flow cytometry and microscopy, respectively. Furthermore, Seahorse analyses, bulk RNA-Seq, and metabolomic analyses were performed to examine the mechanical background. Murine *in vivo* studies are performed to approach the translatability of this system into living organisms.

**Results** CD8<sup>+</sup>Slc2a1 cells possessed a higher proliferative capacity in all conditions tested but most prominently in hypoglycemic (0.5mM) media. This better functional activity of CD8<sup>+</sup>Slc2a1 was also translated to higher killing rates in coculture assays with tumor cells, especially in low-glucose environments. Metabolic flux analyses and multi-omics suggested greater metabolic activity of CD8<sup>+</sup>Slc2a1 and revealed higher ROS production and upregulation of correlating anti-oxidative pathways, especially the pentose-phosphate pathway. Preliminary *in vivo* studies support the *in vitro* killing in a syngeneic tumor model. Furthermore, signs of altered memory formation were visible, expressed in a higher proportion of effector memory cells.

**Conclusions** Our data point to the role of GLUT1 overexpression in T cells for improved cytotoxic activity, proliferation,

and long-term persistence. Therefore, combinatorial approaches with GLUT1 overexpression could serve as a potential approach to increase efficacy in ACT against solid cancer. We also identified GLUT1-dependent reprogramming in CD8<sup>+</sup>Slc2a1 cells which is further investigated in ongoing studies. Additionally, we are evaluating the potential risk of this approach to neoplastic formation.

## REFERENCES

1. Treating hematological malignancies with cell therapy: where are we now? Landoni E, Savoldo B.; *Expert Opin Biol Ther.* 2018.
2. Anticancer targets in the glycolytic metabolism of tumors: a comprehensive review; Paolo E. Porporato *et al. Frontiers in Pharmacology* 2011.
3. Glucose Metabolism on Tumor Plasticity, Diagnosis, and Treatment; Lin Xiaoping *et al. Frontiers in Oncology* 2020
4. Fighting in a wasteland: deleterious metabolites and antitumor immunity. Watson MJ, Delgoffe GM. *J Clin Invest.* 2022.

M.E. Kirmaier: None. B.L. Cadilha: None. A. Hadzic: None. W. Schmitz: None. M.R. Benmebarek: None. D. Briukhovetska: None. S. Michaelides: None. V. Buschinger: None. B. Tast: None. C.H. Bönigk: None. S. Ogenesian: None. L. Vona: None. A. Tischmacher: None. V. Heissmeyer: None. M. Vaeth: None. V.R. Buchholz: None. M. Eilers: None. M. von Bergwelt-Baildon: None. M. Subklewe: None. S. Kobold: None. S. Theurich: None.

**P09.02 LOADING OF CAR-T CELLS WITH SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLES ALLOWS THEIR MAGNETIC TARGETING FOR LOCAL INDUCTION OF ANTIGEN-SPECIFIC ANTI-TUMOR RESPONSES**

<sup>1</sup>F Pfister\*, <sup>1,2</sup>L Löffler, <sup>1</sup>LR Carnell, <sup>1,2</sup>P Boosz, <sup>3</sup>J Dörrie, <sup>3</sup>N Schaft, <sup>1</sup>C Alexiou, <sup>1</sup>C Janko. <sup>1</sup>Department of Otorhinolaryngology, Head and Neck Surgery, Section of Experimental Oncology and Nanomedicine (SEON), Else Kröner-Fresenius-Stiftung Professorship, Universitätsklinikum Erlangen, Germany, Erlangen, Germany; <sup>2</sup>Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany; <sup>3</sup>Department of Dermatology, Universitätsklinikum Erlangen, Comprehensive Cancer Center Erlangen European Metropolitan Area of Nuremberg (CCC ER-EMN), Deutsches Zentrum Immuntherapie (DZI), Bavarian Cancer Research Center (BZKF), Erlangen, Germany, Erlangen, Germany

10.1136/jitc-2024-ITOC10.46

**Background** Different hematological cancer types have shown promising responses to autologous chimeric antigen receptor (CAR)-T cell therapy. However, the efficacy of this treatment in solid tumors is hindered by challenges such as poor tumor infiltration, long-term retention of CAR-T cells, and systemic side effects. To address these limitations, we developed citrate-coated superparamagnetic iron oxide nanoparticles (SPIONs), which have the ability to adhere to and be taken up by T cells, thereby enabling the control of CAR-T cells through an external magnetic field (1-3). In future, magnetic guidability should help to enrich CAR-T cells in the tumor microenvironment, leading to site-specific anti-tumor responses. This study aims to investigate the influence of SPION-loading of CAR-T cells on their efficacy in anti-tumor cell responses *in vitro*.

**Materials and Methods** T cells were isolated from peripheral blood of healthy donors and received mRNA encoding a chondroitin sulfate proteoglycan 4 (CSGP4)-specific CAR via electroporation (4, 5). The cells were then incubated with SPIONs for 4h to magnetically functionalize them. Subsequently, T cells were co-incubated with melanoma tumor cells expressing CSGP4 on their surface. Afterwards, the cells were analyzed for their antigen-specific anti-tumor responses and

compared to non-loaded CAR-T cells or CSGP4-negative tumor cells by flow cytometry. Additionally, tumor cell lysis was investigated via impedance-based monitoring of cell viability and microscopic analysis of the dissolution of three-dimensional tumor spheroids.

**Results** We observed that SPION-loading did not affect the expression of activation markers, differentiation, or proliferation of CAR-T cells. Furthermore, SPION-loaded CAR-T cells retained their capability for antigen-specific tumor cell lysis over multiple days. Additionally, these CAR-T cells demonstrated the ability to be controlled by an external magnetic field, as well as infiltrating and dissolving tumor spheroids.

**Conclusions** In summary, we demonstrated that SPION-loading did not compromise the functionality of CAR-T cells, as they were still able to perform the investigated effector functions with similar efficacy as the non-loaded control CAR-T cells. These findings underscore the potential of SPIONs in enhancing site-specific anti-tumor responses of CAR-T cells in the therapy of solid cancers in the future.

## REFERENCES

1. Mühlberger et al. *J. Magn.* 2019.
2. Boosz et al. *Cancers.* 2021.
3. Pfister et al. *Front Immunol.* 2023.
4. Krug et al. *Cancer Immunol Immunother.* 2015.
5. Harrer et al. *Int J Mol Sci.* 2019.

F. Pfister: None. L. Löffler: None. L.R. Carnell: None. P. Boosz: None. J. Dörrie: None. N. Schaft: None. C. Alexiou: None. C. Janko: None.

P09.03

### LOADING OF T CELLS WITH SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLES GIVES THEM MAGNETIC CONTROLLABILITY WHILE RETAINING ANTIGEN-SPECIFIC EFFECTOR FUNCTIONS

<sup>1</sup>LR Carnell\*, <sup>1,2</sup>S Knorr, <sup>1</sup>F Pfister, <sup>3</sup>J Dörrie, <sup>3</sup>N Schaft, <sup>1</sup>C Alexiou, <sup>1</sup>C Janko. <sup>1</sup>Department of Otorhinolaryngology, Head and Neck Surgery, Section of Experimental Oncology and Nanomedicine (SEON), Universitätsklinikum, Erlangen, Germany; <sup>2</sup>Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany; <sup>3</sup>Department of Dermatology, Universitätsklinikum Erlangen, Comprehensive Cancer Center Erlangen European Metropolitan Area of Nuremberg (CCC ER-EMN), Deutsches Zentrum Immuntherapie (DZI), Bavarian Cancer Research Center (BZKF), Erlangen, Germany

10.1136/jitc-2024-ITOC10.47

**Background** The composition of the tumor microenvironment in solid tumors is of crucial importance for the prognosis and clinical outcome of patients with solid cancers (1). Infiltration of CD8+ T cells into the tumor can improve the prognosis and treatment options of patients. Adoptive T cell therapy is intended to increase the number of CD8+ T cells in the tumor. However, only a fraction of cancer patients benefit from this option, partially because the T cells do not effectively reach the tumor (2). We developed citrate-coated superparamagnetic iron oxide nanoparticles (SPIONs) for the loading of T cells to make them magnetically controllable (3,4). After intra-arterial application and magnetic enrichment in the tumor region, SPION-loaded T cells must pass through the vessel wall to reach the tumor and they must retain antigen-specific effector functions to fight the tumor. This study investigated the effects of SPION loading on primary human T cells, particularly on antigen-specific effector functions and their cellular migration capacity (5).

**Materials and Methods** T cells were freshly isolated from human whole blood and subsequently loaded with SPIONs for 4 h. Unloaded T cells served as controls. Using a Boyden-Chamber-based assay, we acquired information about the ability of T cell to migrate towards a CXCL12-gradient. Furthermore, the tethering and attachment of T cells on an endothelial cell monolayer was investigated by fluorescence microscopy. The deformability upon SPION-loading was investigated using Real-Time Deformability Cytometry (RT-DC). Antigen-specific effector functions were examined after stimulation via an introduced exogenous T cell receptor (TCR) specific for the melanoma antigen MelanA or the endogenous TCR specific for the cytomegalovirus antigen pp65.

**Results** SPION-loading had no effect on the attachment of T cells to an endothelial monolayer, however, the chemotactic migration was reduced by SPIONs, which was cancelled out by magnetic attraction. RT-DC ruled out stiffening of the cells due to nanoparticle loading, which is important for squeezing through the vessel walls during transmigration. Lastly, we observed no alterations in antigen-specific effector functions regarding proliferation, expression of activation markers, cytokine secretion, or tumor cell killing after antigen-specific activation mediated by endo- or exogenous TCRs.

**Conclusions** In sum, we showed that SPION loading did not impair cellular mechanics or antigen-specific effector functions. With regard to cell transmigration, possible negative effects of SPION-loading on the T cells were compensated by magnetic attraction. These results underline the potential of SPIONs for the enrichment of T cells in the tissue of solid tumors through magnetic attraction.

## REFERENCES

1. Giraldo NA, et al. *Br J Cancer* 2019.
2. Morotti, M, et al. *Br J Cancer* 2021.
3. Boosz P, et al. *Cancers* 2021.
4. Mühlberger M, et al. *Int J Nanomedicine* 2019.
5. Pfister F, et al. *Front Immunol* 2023.

L.R. Carnell: None. S. Knorr: None. F. Pfister: None. J. Dörrie: None. N. Schaft: None. C. Alexiou: None. C. Janko: None.

P09.04

### ISOLATION OF A HIGH AVIDITY TCR TARGETING A NEWLY IDENTIFIED EPITOPE OF A COMMON CANCER TESTIS ANTIGEN EXPRESSED BY SOLID TUMORS

<sup>1,2</sup>E Sivo\*, <sup>1,3</sup>M Klatt, <sup>1</sup>S Elezkurtaj, <sup>1,2</sup>C Freund, <sup>1,2</sup>C Grunert, <sup>1,2,3</sup>U Keller, <sup>1,2,3</sup>A Busse. <sup>1</sup>Charité-Universitätsmedizin Berlin, Berlin, Germany; <sup>2</sup>Max Delbrück Center for Molecular Medicine, Berlin, Germany; <sup>3</sup>German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), Heidelberg, Germany

10.1136/jitc-2024-ITOC10.48

**Background** T cell receptor (TCR)-based immunotherapy is a promising cancer treatment particularly as the TCR antigen repertoire detects both intracellular and extracellular tumor antigens. Our newly identified cancer-testis antigen (CTA) is an intracellular antigen exclusively expressed by cancer and reproductive tissue making it an ideal target for TCR-T cell therapy. Here, we aim to isolate a TCR against an HLA-A\*02:01 restricted CTA epitope from the human HLA-A\*02:01 negative repertoire to evaluate its safety and efficacy *in vitro* and *in vivo*.